ARTICLE | Clinical News
EV06: Phase I/II started
October 12, 2015 7:00 AM UTC
Encore began a double-blind, placebo-controlled, U.S. Phase I/II trial to evaluate twice-daily topical EV06 for 90 days in about 72 patients ages 45-55. ...
Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
Encore began a double-blind, placebo-controlled, U.S. Phase I/II trial to evaluate twice-daily topical EV06 for 90 days in about 72 patients ages 45-55. ...